Source Articles
Avelumab
Showing 3 study arms
with grade ≥3 adverse event data (treatment-related and RT-related).
Click a column header to sort.
Note on patient counts: some articles reported only percentages rather
than absolute numbers. Where this occurred, the number of patients — including those with
grade ≥3 adverse events — was derived by applying the reported percentage to the total arm
size, which may produce a non-integer value. These figures have been rounded to the nearest
integer for display.
| 1st Author | Year | Study Type | Title | DOI | clinical trial number | number of patients | median/mean age | median follow-up [months] | tumor type | treatment setting | drug group | drug name | if other, please specify | number of SBRT courses | intracranial / extracranial | treated site | If other treated site, please specify | median/mean total RT dose [Gy] | minimum total RT dose [Gy] | maximum total RT dose [Gy] | median/mean number of fractions | minimum number of fractions | maximum number of fractions | median/mean dose per fraction [Gy] | minimum dose per fraction [Gy] | maximum dose per fraction [Gy] | toxicity type | patients with acute G>=3 toxicity | patients with late G>=3 toxicity | patients with G>=3 toxicity, timing unspecified | G>=3 AEs | patients with G>=3 AEs | details on G>=3 toxicity | details on G>=3 toxicity in RT field |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiang et al. | 2023 | Prospective | Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial | 10.1016/s2468-1253(22)00339-9 | — | 33 | 68 | 17.2 | HCC | primary | Anti-PD-(L)1 mAb | Avelumab | also TACE | 33 | extra-cranial | liver | — | 30 | 30 | 35 | 5 | 5 | 5 | — | — | — | Treatment-rel. | — | — | 11 | G3: 24 AE, G4: 9 AE | G3: 3 pt, G4: 8 pt |
any G3: ascites, weight gained, dizziness, hoarseness, maculopapular rash, urticarial rash, pruritis, dry skin, nausea, alanine aminotransferase increased, Aspartate aminotransferase increased, Gamma-glutamyl transferase increased, bilirubin increased, Alkaline phosphatase increased, hepatitis, dermatitis, any G4: weight gained, dizziness, hoarseness, Alanine aminotransferase increased, Aspartate aminotransferase increased, Hyponatraemia
|
—
|
| Rimner et al. | 2023 | Prospective | A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma | 10.1016/j.jtocrr.2022.100440 | NCT03399552 | 13 | 71 | 8.9 | other | any | Anti-PD-(L)1 mAb | Avelumab | — | 13 | both | Missing | — | 30 | 24 | 35 | 3 | 3 | 5 | 10.0 | Missing | Missing | Treatment-rel. | — | — | 2 | any G3: 4 AEs | any G3: 2 pts |
any G3: Infusion-related allergic reaction, chest wall pain, myalgia, anorexia
|
any G3: Chest wall pain
|
| Kwan et al. | 2022 | Prospective | Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial | 10.1016/j.eururo.2021.08.011 | ACTRN12618000954224 | 31 | 71 | 18.0 | Prostate cancer | oligometastatic | Anti-PD-(L)1 mAb | Avelumab | — | 31 | extra-cranial | bone | — | 20 | 20 | 20 | 1 | 1 | 1 | 20.0 | 20 | 20 | Treatment-rel. | — | — | 5 | Missing | any G3 or G4: 5 pt |
any G3 or G4: Infusion related reaction, bone pain, maculopapular rash, hyperglycemia, pneumonitis
|
—
|